RARE
Ultragenyx Pharmaceutical Inc
Price:  
37.14 
USD
Volume:  
1,200,712.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RARE EV/EBITDA

-434.9%
Upside

As of 2025-06-21, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,384.16 mil USD. RARE's TTM EBITDA according to its financial statements is -540.93 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 11.9x - 12.4x 12.2x
Forward P/E multiples 20.2x - 43.4x 31.8x
Fair Price (114.24) - (69.61) (124.39)
Upside -407.6% - -287.4% -434.9%
37.14 USD
Stock Price
(124.39) USD
Fair Price

RARE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2025-06-06 -6.26
2025-06-05 -6.22
2025-06-04 -6.16
2025-06-03 -6.13
2025-06-02 -6.08
2025-05-30 -5.71
2025-05-29 -5.89
2025-05-28 -5.77
2025-05-27 -5.90
2025-05-23 -6.00
2025-05-22 -5.97
2025-05-21 -5.95
2025-05-20 -6.29
2025-05-19 -6.09
2025-05-16 -5.99
2025-05-15 -5.85
2025-05-14 -5.83
2025-05-13 -5.95
2025-05-12 -6.07
2025-05-09 -5.90
2025-05-08 -6.05
2025-05-07 -5.61
2025-05-06 -5.89
2025-05-05 -6.56
2025-05-02 -6.63
2025-05-01 -6.58
2025-04-30 -6.58
2025-04-29 -6.42
2025-04-28 -6.40
2025-04-25 -6.42
2025-04-24 -6.34
2025-04-23 -6.29
2025-04-22 -6.04
2025-04-21 -5.95
2025-04-17 -6.00
2025-04-16 -5.88
2025-04-15 -5.94
2025-04-14 -5.87
2025-04-11 -5.73
2025-04-10 -5.56
2025-04-09 -5.69
2025-04-08 -5.19
2025-04-07 -5.38
2025-04-04 -5.43
2025-04-03 -5.90
2025-04-02 -5.95
2025-04-01 -5.68
2025-03-31 -6.09
2025-03-28 -6.37
2025-03-27 -6.56